Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction

Possible eradication of minimal residual disease by marrow transplantation

K. Miyamura, M. Tanimoto, Y. Morishima, K. Horibe, K. Yamamoto, Yoshiki Akatsuka, Y. Kodera, S. Kojima, K. Matsuyama, N. Hirabayashi, M. Yazaki, K. Imai, Y. Onozawa, A. Kanamaru, S. Mizutani, H. Saito

研究成果: Article

92 引用 (Scopus)

抄録

Minimal residual disease (MRD) in patients with Philadelphia chromosome- positive acute lymphoblastic leukemia (Ph1 ALL) who received allogeneic (n = 9) or autologous (n = 6) bone marrow transplantation (BMT) was evaluated by the polymerase chain reaction (PCR) for the bcr-abl transcript. Twelve patients received BMT at the time of hematologic and cytogenetic remission. However, MRD was detected in 8 of 10 patients evaluated. Seven patients, including three who had MRD before BMT, continue to have a disease-free survival 5 to 64 months after BMT. Twenty-one specimens obtained from these patients at various times after BMT did not show MRD. In three patients, MRD detected just before BMT seems to be eradicated by BMT protocol. The other eight patients developed cytogenetic or hematologic relapses 2 to 8 months after BMT. Seven of 14 samples from these patients demonstrated MRD, which preceded clinical relapse by 3 to 9 weeks. Thus, this technique for the detection of MRD appears to be useful for the more precise assessment of various antileukemia therapies and for early detection of leukemia recurrence.

元の言語English
ページ(範囲)1366-1370
ページ数5
ジャーナルBlood
79
発行部数5
出版物ステータスPublished - 01-01-1992
外部発表Yes

Fingerprint

Philadelphia Chromosome
Polymerase chain reaction
Residual Neoplasm
Chromosomes
Bone Marrow Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone
Transplantation
Bone Marrow
Polymerase Chain Reaction
Recurrence
Cytogenetics
Disease-Free Survival
Leukemia

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

これを引用

Miyamura, K., Tanimoto, M., Morishima, Y., Horibe, K., Yamamoto, K., Akatsuka, Y., ... Saito, H. (1992). Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: Possible eradication of minimal residual disease by marrow transplantation. Blood, 79(5), 1366-1370.
Miyamura, K. ; Tanimoto, M. ; Morishima, Y. ; Horibe, K. ; Yamamoto, K. ; Akatsuka, Yoshiki ; Kodera, Y. ; Kojima, S. ; Matsuyama, K. ; Hirabayashi, N. ; Yazaki, M. ; Imai, K. ; Onozawa, Y. ; Kanamaru, A. ; Mizutani, S. ; Saito, H. / Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction : Possible eradication of minimal residual disease by marrow transplantation. :: Blood. 1992 ; 巻 79, 番号 5. pp. 1366-1370.
@article{cc2bd86a68a042baa2ee832c2e176329,
title = "Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: Possible eradication of minimal residual disease by marrow transplantation",
abstract = "Minimal residual disease (MRD) in patients with Philadelphia chromosome- positive acute lymphoblastic leukemia (Ph1 ALL) who received allogeneic (n = 9) or autologous (n = 6) bone marrow transplantation (BMT) was evaluated by the polymerase chain reaction (PCR) for the bcr-abl transcript. Twelve patients received BMT at the time of hematologic and cytogenetic remission. However, MRD was detected in 8 of 10 patients evaluated. Seven patients, including three who had MRD before BMT, continue to have a disease-free survival 5 to 64 months after BMT. Twenty-one specimens obtained from these patients at various times after BMT did not show MRD. In three patients, MRD detected just before BMT seems to be eradicated by BMT protocol. The other eight patients developed cytogenetic or hematologic relapses 2 to 8 months after BMT. Seven of 14 samples from these patients demonstrated MRD, which preceded clinical relapse by 3 to 9 weeks. Thus, this technique for the detection of MRD appears to be useful for the more precise assessment of various antileukemia therapies and for early detection of leukemia recurrence.",
author = "K. Miyamura and M. Tanimoto and Y. Morishima and K. Horibe and K. Yamamoto and Yoshiki Akatsuka and Y. Kodera and S. Kojima and K. Matsuyama and N. Hirabayashi and M. Yazaki and K. Imai and Y. Onozawa and A. Kanamaru and S. Mizutani and H. Saito",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "79",
pages = "1366--1370",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

Miyamura, K, Tanimoto, M, Morishima, Y, Horibe, K, Yamamoto, K, Akatsuka, Y, Kodera, Y, Kojima, S, Matsuyama, K, Hirabayashi, N, Yazaki, M, Imai, K, Onozawa, Y, Kanamaru, A, Mizutani, S & Saito, H 1992, 'Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: Possible eradication of minimal residual disease by marrow transplantation', Blood, 巻. 79, 番号 5, pp. 1366-1370.

Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction : Possible eradication of minimal residual disease by marrow transplantation. / Miyamura, K.; Tanimoto, M.; Morishima, Y.; Horibe, K.; Yamamoto, K.; Akatsuka, Yoshiki; Kodera, Y.; Kojima, S.; Matsuyama, K.; Hirabayashi, N.; Yazaki, M.; Imai, K.; Onozawa, Y.; Kanamaru, A.; Mizutani, S.; Saito, H.

:: Blood, 巻 79, 番号 5, 01.01.1992, p. 1366-1370.

研究成果: Article

TY - JOUR

T1 - Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction

T2 - Possible eradication of minimal residual disease by marrow transplantation

AU - Miyamura, K.

AU - Tanimoto, M.

AU - Morishima, Y.

AU - Horibe, K.

AU - Yamamoto, K.

AU - Akatsuka, Yoshiki

AU - Kodera, Y.

AU - Kojima, S.

AU - Matsuyama, K.

AU - Hirabayashi, N.

AU - Yazaki, M.

AU - Imai, K.

AU - Onozawa, Y.

AU - Kanamaru, A.

AU - Mizutani, S.

AU - Saito, H.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Minimal residual disease (MRD) in patients with Philadelphia chromosome- positive acute lymphoblastic leukemia (Ph1 ALL) who received allogeneic (n = 9) or autologous (n = 6) bone marrow transplantation (BMT) was evaluated by the polymerase chain reaction (PCR) for the bcr-abl transcript. Twelve patients received BMT at the time of hematologic and cytogenetic remission. However, MRD was detected in 8 of 10 patients evaluated. Seven patients, including three who had MRD before BMT, continue to have a disease-free survival 5 to 64 months after BMT. Twenty-one specimens obtained from these patients at various times after BMT did not show MRD. In three patients, MRD detected just before BMT seems to be eradicated by BMT protocol. The other eight patients developed cytogenetic or hematologic relapses 2 to 8 months after BMT. Seven of 14 samples from these patients demonstrated MRD, which preceded clinical relapse by 3 to 9 weeks. Thus, this technique for the detection of MRD appears to be useful for the more precise assessment of various antileukemia therapies and for early detection of leukemia recurrence.

AB - Minimal residual disease (MRD) in patients with Philadelphia chromosome- positive acute lymphoblastic leukemia (Ph1 ALL) who received allogeneic (n = 9) or autologous (n = 6) bone marrow transplantation (BMT) was evaluated by the polymerase chain reaction (PCR) for the bcr-abl transcript. Twelve patients received BMT at the time of hematologic and cytogenetic remission. However, MRD was detected in 8 of 10 patients evaluated. Seven patients, including three who had MRD before BMT, continue to have a disease-free survival 5 to 64 months after BMT. Twenty-one specimens obtained from these patients at various times after BMT did not show MRD. In three patients, MRD detected just before BMT seems to be eradicated by BMT protocol. The other eight patients developed cytogenetic or hematologic relapses 2 to 8 months after BMT. Seven of 14 samples from these patients demonstrated MRD, which preceded clinical relapse by 3 to 9 weeks. Thus, this technique for the detection of MRD appears to be useful for the more precise assessment of various antileukemia therapies and for early detection of leukemia recurrence.

UR - http://www.scopus.com/inward/record.url?scp=0026581805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026581805&partnerID=8YFLogxK

M3 - Article

VL - 79

SP - 1366

EP - 1370

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -